Switzerland’s OncoEthix has raised $19 million in venture cash to back its work on an early-stage cancer treatment, one of a new class of oncology drugs that’s been inspiring a range of new clinical trials. SV Life Sciences (SVLS) led the Series B, joined by new investor Edmond de Rothschild Investment Partners and assisted by Index Ventures and Endeavour Vision, which helped raise the biotech’s total to $30 million.
